glp 1 agonists and inflammation Frontiers GLP-1 Receptor Agonists Reduce Inflammation
Description
9-11 It should be noted that there are several well-designed landmark trials investigating a GLP-1 RA in addition to basal insulin with placebo or other comparators
In landmark trials such as LEADER and SUSTAIN-6, liraglutide significantly lowered the risk of cardiovascular death, non-fatal myocardial infarction, and stroke by 13% compared to placebo (Marso et al., 2016a)
They are also administered at different doses and last for different durations
10.1016/j.diabres.2014.04.006 24
